title: Dynamics of docosahexaenoic acid metabolism in the central nervous system: lack of effect of chronic lithium treatment.
abstract: Using a method and model developed in our laboratory to quantitatively study brain phospholipid metabolism, in vivo rates of incorporation and turnover of docosahexaenoic acid in brain phospholipids were measured in awake rats. The results suggest that docosahexaenoate incorporation and turnover in brain phospholipids are more rapid than previously assumed and that this rapid turnover dilutes tracer specific activity in brain docoshexaenoyl-CoA pool due to release and recycling of unlabeled fatty acid from phospholipid metabolism. Fractional turnover rates for docosahexaenoate within phosphatidylinositol, choline glycerophospholipids, ethanolamine glycerophospholipids and phosphatidylserine were 17.7, 3.1, 1.2, and 0.2 %.h(-1), respectively. Chronic lithium treatment, at a brain level considered to be therapeutic in humans (0.6 micromol.g(-1)), had no effect on turnover of docosahexaenoic acid in individual brain phospholipids. Consistent with previous studies from our laboratory that chronic lithium decreased the turnover of arachidonic acid within brain phospholipids by up to 80% and attenuated brain phospholipase A2 activity, the lack of effect of lithium on docosahexaenoate recycling and turnover suggests that a target for lithium's action is an arachidonic acid-selective phospholipase A2.
authors.affiliation: Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA. mcjchang@box-m.nih.gov
authors.forename: M C
authors.initials: MC
authors.lastname: Chang
authors.forename: J M
authors.initials: JM
authors.lastname: Bell
authors.forename: A D
authors.initials: AD
authors.lastname: Purdon
authors.forename: E G
authors.initials: EG
authors.lastname: Chikhale
authors.forename: E
authors.initials: E
authors.lastname: Grange
mesh_terms: D000214:Acyl Coenzyme A / Q000378:metabolism; D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D004281:Docosahexaenoic Acids / Q000097:blood / Q000378:metabolism*; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D050356:Lipid Metabolism; D008094:Lithium / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D010741:Phospholipases A / Q000378:metabolism; D054467:Phospholipases A2; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000214:Acyl Coenzyme A; D005230:Fatty Acids, Nonesterified; D010743:Phospholipids; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; D008094:Lithium; D010741:Phospholipases A; D054467:Phospholipases A2